|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Innoviva, Inc. 10-K 12/31/23 100:23M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 4.39M
2: EX-21.1 Subsidiaries List HTML 37K
3: EX-23.1 Consent of Expert or Counsel HTML 28K
4: EX-23.2 Consent of Expert or Counsel HTML 28K
8: EX-97 Clawback Policy re: Recovery of Erroneously HTML 52K
Awarded Compensation
5: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
7: EX-32 Certification -- §906 - SOA'02 HTML 33K
10: R1 Document and Entity Information HTML 101K
11: R2 Consolidated Balance Sheets HTML 149K
12: R3 Consolidated Balance Sheets (Parenthetical) HTML 51K
13: R4 Consolidated Statements of Income HTML 132K
14: R5 Consolidated Statements of Income (Parenthetical) HTML 32K
15: R6 Consolidated Statements of Comprehensive Income HTML 53K
16: R7 Consolidated Statements of Stockholders' Equity HTML 161K
17: R8 Consolidated Statements of Cash Flows HTML 162K
18: R9 Insider Trading Arrangements HTML 38K
19: R10 Description of Operations and Summary of HTML 115K
Significant Accounting Policies
20: R11 Net Income Per Share HTML 103K
21: R12 Revenue Recognition HTML 75K
22: R13 License and Collaboration Arrangements HTML 65K
23: R14 Consolidated Entities and Acquisitions HTML 155K
24: R15 Equity and Long-Term Investments and Fair Value HTML 337K
Measurements
25: R16 Capitalized Fees Paid HTML 56K
26: R17 Goodwill and Intangible Assets HTML 85K
27: R18 Balance Sheet Components HTML 86K
28: R19 Stock-Based Compensation HTML 172K
29: R20 Stockholders' Equity HTML 40K
30: R21 Debt HTML 195K
31: R22 Commitments and Contingencies HTML 79K
32: R23 Income Taxes HTML 164K
33: R24 Subsequent Events HTML 34K
34: R25 Description of Operations and Summary of HTML 175K
Significant Accounting Policies (Policies)
35: R26 Description of Operations and Summary of HTML 34K
Significant Accounting Policies (Tables)
36: R27 Net Income Per Share (Tables) HTML 101K
37: R28 Revenue Recognition (Tables) HTML 56K
38: R29 Consolidated Entities and Acquisitions (Tables) HTML 130K
39: R30 Equity and Long-Term Investments and Fair Value HTML 287K
Measurements (Tables)
40: R31 Capitalized Fees Paid (Tables) HTML 52K
41: R32 Goodwill and Intangible Assets (Tables) HTML 77K
42: R33 Balance Sheet Components (Tables) HTML 86K
43: R34 Stock-Based Compensation (Tables) HTML 160K
44: R35 Debt (Tables) HTML 157K
45: R36 Commitments and Contingencies (Tables) HTML 68K
46: R37 Income Taxes (Tables) HTML 156K
47: R38 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 76K
SIGNIFICANT ACCOUNTING POLICIES - Description of
Operations (Details)
48: R39 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 37K
SIGNIFICANT ACCOUNTING POLICIES - Property and
Equipment (Details)
49: R40 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 33K
SIGNIFICANT ACCOUNTING POLICIES - Related Party
Transactions (Details)
50: R41 Net Income Per Share (Details) HTML 44K
51: R42 Net Income Per Share - Basic and Diluted EPS HTML 76K
(Details)
52: R43 NET INCOME PER SHARE - Anti-Dilutive Securities HTML 37K
(Details)
53: R44 REVENUE RECOGNITION - Schedule of net revenue from HTML 53K
collaborative arrangements (Details)
54: R45 Revenue Recognition (Details) HTML 98K
55: R46 LICENSE AND COLLABORATION ARRANGEMENTS - HTML 99K
Additional Information (Details)
56: R47 CONSOLIDATED ENTITIES AND ACQUISITIONS - HTML 119K
Theravance Respiratory Company, LLC (Details)
57: R48 CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund HTML 72K
LP (Details)
58: R49 CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis HTML 92K
Therapeutics Holdings, Inc. (Details)
59: R50 CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule HTML 91K
of Recognized Identified Assets Acquired and
Liabilities Assumed (Details)
60: R51 CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla HTML 52K
Pharmaceutical Company (Details)
61: R52 CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma HTML 48K
Information (Details)
62: R53 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 133K
MEASUREMENTS - Equity Investment in Armata
(Details)
63: R54 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 90K
MEASUREMENTS - Summarized Financial Data (Details)
64: R55 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 113K
MEASUREMENTS - Equity Investment in InCarda
(Details)
65: R56 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 55K
MEASUREMENTS - Equity Investment in ImaginAb
(Details)
66: R57 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 59K
MEASUREMENTS - Convertible Promissory Note in Gate
Neurosciences (Details)
67: R58 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 49K
MEASUREMENTS - Equity Investment in Nanolive
(Details)
68: R59 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 49K
MEASUREMENTS - Available-for-Sale Securities
(Details)
69: R60 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 162K
MEASUREMENTS - Schedule of Available-for-Sale
Securities Measured at Fair Value on a Recurring
Basis (Details)
70: R61 CAPITALIZED FEES PAID - Schedule of Capitalized HTML 64K
Fees Paid (Details)
71: R62 Goodwill and Intangible Assets (Additional HTML 77K
Information) (Details)
72: R63 Goodwill and Intangible Assets - Summary of HTML 58K
Accumulated Amortization of Recognized Intangible
Assets (Details)
73: R64 BALANCE SHEET COMPONENTS - Schedule of Inventory, HTML 38K
net (Details)
74: R65 BALANCE SHEET COMPONENTS - Additional Information HTML 34K
(Details)
75: R66 BALANCE SHEET COMPONENTS - Schedule Of Other HTML 51K
Accrued Liabilities (Details)
76: R67 BALANCE SHEET COMPONENTS -Schedule of Other HTML 38K
Long-term Liabilities (Details)
77: R68 STOCK-BASED COMPENSATION - 2012 Plan and ESPP HTML 63K
(Details)
78: R69 STOCK-BASED COMPENSATION - Director Compensation HTML 47K
Program (Details)
79: R70 STOCK-BASED COMPENSATION - Stock-Based HTML 60K
Compensation Expense (Details)
80: R71 STOCK-BASED COMPENSATION - Compensation Awards HTML 127K
(Details)
81: R72 STOCK-BASED COMPENSATION - Valuation Assumptions HTML 43K
(Details)
82: R73 Stockholders' Equity (Details) HTML 41K
83: R74 DEBT - Schedule of Debt (Details) HTML 81K
84: R75 DEBT - Convertible Subordinated Notes (Details) HTML 124K
85: R76 DEBT - Convertible Senior Notes (Details) HTML 184K
86: R77 DEBT - Debt Maturities (Details) HTML 45K
87: R78 COMMITMENTS AND CONTINGENCIES - Additional HTML 42K
Information (Details)
88: R79 COMMITMENTS AND CONTINGENCIES - Schedule of HTML 35K
Components of Least Cost (Details)
89: R80 COMMITMENTS AND CONTINGENCIES - Schedule of HTML 35K
Supplemental Cash Flow Information Related to
Lease (Details)
90: R81 COMMITMENTS AND CONTINGENCIES - Schedule of Future HTML 45K
Minimum Lease Payments (Details)
91: R82 INCOME TAXES - Income tax expense (Details) HTML 51K
92: R83 INCOME TAXES - Reconciliation (Details) HTML 51K
93: R84 INCOME TAXES - Deferred Taxes (Details) HTML 57K
94: R85 INCOME TAXES - Additional Tax Disclosures HTML 56K
(Details)
95: R86 SUBSEQUENT EVENTS - Additional Information HTML 58K
(Details)
97: XML IDEA XML File -- Filing Summary XML 194K
100: XML XBRL Instance -- inva-20231231_htm XML 4.36M
96: EXCEL IDEA Workbook of Financial Report Info XLSX 261K
9: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 6.62M
Linkbases Document -- inva-20231231
98: JSON XBRL Instance as JSON Data -- MetaLinks 804± 1.29M
99: ZIP XBRL Zipped Folder -- 0000950170-24-023237-xbrl Zip 2.83M
| EX-31.2 |
Exhibit 31.2
Certification of Principal Accounting Officer
Pursuant to Section 302 of the Sarbanes‑Oxley Act of 2002
I, Stephen Basso, certify that:
1. I have reviewed this Annual Report on Form 10‑K of Innoviva, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a‑15(e) and 15d‑15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a‑15(f) and 15(d)‑15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: |
|
/s/ STEPHEN BASSO |
|
|
|
||
|
|
Chief Financial Officer |
|
|
|
(Principal Financial Officer) |
|
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/29/24 | 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/22/24 Innoviva, Inc. 10-K/A 12/31/23 13:4.7M Donnelley … Solutions/FA 3/05/24 Innoviva, Inc. 10-K/A 12/31/23 96:16M Donnelley … Solutions/FA |